Purpose To investigate the association between KRAS mutation and prognosis in rectal
cancer patients with neoadjuvant chemoradiotherapy. Methods Literature was searched in …

INTRODUCTION: The current management of locally advanced rectal cancer involves total
mesorectal excision, which may be preceded by neo-adjuvant chemoradiotherapy (CRT) …

Individual patient response to neoadjuvant treatment is variable and reproducible
biomarkers of response are needed. The role of the V-Ki-ras2 Kirsten rat sarcoma viral …

Background The prognostic value of the KRAS proto-oncogene mutation in colorectal
cancer has been debated. Herein, we analyzed the National Cancer Database (NCDB) to …

We evaluated the tumor response and survival according to the KRAS oncogene status in
locally advanced rectal cancer. One hundred patients with locally advanced rectal cancer …

Background Mutations in KRAS and TP53 are common in colorectal carcinogenesis and are
associated with resistance to therapy. Rectal cancers carrying both mutations are less likely …

Background The response of rectal cancers to neoadjuvant chemoradiation (CRT) is
variable, but tools to predict response remain lacking. We evaluated whether KRAS and …

Background Mutation of the KRAS oncogene (mKRAS) in colorectal cancer has been
associated with aggressive tumor biology, resistance to epidermal growth factor inhibitors …

Background/Aim: Complete clinical response in rectal cancer after neoadjuvant chemo-
radiotherapy is challenging. Indeed, indication to surgery vs.“watch and wait” is a debate …

Background Conventional treatment for locally advanced rectal cancer usually combines
neoadjuvant radiochemotherapy and surgery. Until recently, there have been limited …